113 results about "Cancer cell lines" patented technology

The invention belongs to the field of bioinformatics, and relates to an anti-cancer drug response prediction method based on an attention mechanism. The method comprises the following steps: firstly, capturing uniform-dimension drug and cancer cell line characteristics through a multi-layer perceptron; secondly, fusing drug characteristics by adopting a Transform encoder, and constructing a cell encoder for cancer cell line characteristic polymerization; then, designing a cross-modal cross fusion module to promote information interaction between the two; and finally, predicting a semi-suppressed concentration value subjected to logarithmic transformation between the two through a multi-layer perceptron. Experimental results show that compared with an existing optimal method, the method has the advantage that the RMSE is reduced by 2.9%. According to the method, accurate prediction of the anti-cancer drug response is achieved by integrating drug and cancer cell line data, screening of potential anti-cancer drugs can be accelerated, personalized treatment schemes can be optimized, the cure rate of cancer patients is further increased, and the method has great significance in cancer treatment.

The invention discloses an anti-cancer drug synergistic effect prediction method based on deep learning, and the method can employ a network model which comprises a data input module, a drug sub-network module, a CrossNet module and a collaborative score prediction module. The data input is used for inputting drug pair-cell line characteristic data and cell line types, tissue types and cancer subtype data under the combined action of the two drugs, and the drug pair-cell line characteristic data comprises drug chemical characteristic data of the two drugs and cancer cell line gene expression data under the combined action of the two drugs; the input of the medicine sub-network module and the input of the CrossNet module are data output by the data input module; and the input of the collaborative score prediction module is the output of the drug sub-network module and the output of the CrossNet module. The method provided by the invention can more accurately and reliably predict whether the anticancer drugs have a synergistic effect.

The invention discloses a dual-channel fusion cancer drug response prediction method, and belongs to the technical field of biological information. The method aims at solving the problems that an existing prediction method is only limited to intra-modal feature extraction, and a complex nonlinear cooperative relation between a drug and cancer cells is difficult to capture. Multi-omics data, drug molecular structure information and cancer cell line drug reaction data are integrated from databases such as CCLE, GDSC and PubChem, and unified input features are formed through standardization and feature construction. Introducing a hierarchical double-attention conversion network into the first channel to carry out characterization learning on the multi-modal features of the drug and the cell line, and constructing a high-order attention neighbor interaction graph convolutional network in the second channel to capture graph structure information of cancer drug response. And carrying out adaptive weighting on output results of the two channels by using a PPO-based fusion module so as to realize a dynamic optimal decision. And finally, generating a drug sensitivity prediction result of the cancer cell line through a classification predictor.

Methods for facilitating drug discovery in various models and proposing single cell-type-specific drug candidates, and predicting cellular drug sensitivities. Predictions comprise obtaining bulk RNA sequence data, wherein bulk RNA seq data is pan-cancer cell line transcriptomic data from one or more sources; obtaining single cell RNA sequence data (scRNA-seq) from one or more sources; integrating the bulk RNA sequence data and scRNA-seq data; capturing similarities between the bulk data and the scRNA-seq data based on a shared drug response relative gene and using canonical correlation analysis; extracting one or more drug-response relevant features and selecting a pharmacogenomic subspace for accurately predicting a single-cell drug response.

Disclosed is an anticancer composition using a flavone derivative. In the present invention, the flavone derivative exhibits cytotoxicity against: H827, H1299, H522, and A549, which are human non-small cell lung cancer cell lines; MCF-7, which is a human breast cancer cell line; and PANC-1, which is a human pancreatic cancer cell line, in a time-dependent manner and in a treatment concentration-dependent manner, and not only exhibits a synergistic effect when used in combination with other conventional anticancer agents, such as osimertinib, which is an anticancer agent targeting for lung cancer, tamoxifen, which is a hormone agent against breast cancer, and gemcitabine, which is a cytotoxic anticancer agent against pancreatic cancer, but also exhibits the effect of synergistically inhibiting the expression of HIF-1α when used alone or in combination with an existing anticancer agent.

The invention discloses a CDK2 / 4 / 6 proteolysis targeting chimera as well as a preparation method, a pharmaceutical composition and application thereof, and the chemical structure of the CDK2 / 4 / 6 proteolysis targeting chimera is shown as a formula I, the CDK2 / 4 / 6 proteolysis targeting chimera or the isomer, the pharmaceutically acceptable salt, the solvate, the prodrug, the deuterated compound or the polymorphic substance thereof can induce selective degradation of CDK2, CDK4 and CDK6 through ubiquitin-proteasome, so that the phosphorylation level of RB1 is reduced, release of a transcription factor E2F is further inhibited, the process of cells from a G1 phase to an S phase is blocked, and the targeting effect of the cells is improved. Compared with an inhibitor, the compound is more efficient and low in toxicity, and can be used for treating various cancers. # imgabs0 #

The invention relates to the technical field of medicines, and discloses an application of combination of bufalin and heme in preparation of a cancer treatment medicine. According to the invention, by means of an active metabonomics means, a key active metabolite-heme is locked through exogenous library screening and endogenous analysis, and the drug effect of bufalin is regulated by means of the active metabolite. Through verification, it is found that heme can cooperate with the synergistic drug effect in various cancer cell lines, and a new technical normal form based on an active metabolome for improving the drug effect of bufalin is provided. The pharmaceutical composition can improve the apoptosis induction ability of bufalin to different cancer cells, and provides powerful guiding significance for developing a novel treatment scheme in clinical medicine.

The invention relates to the technical field of bioinformatics, in particular to a drug response prediction method based on knowledge graph and multi-view comparative learning, which comprises the following steps: acquiring drug response information and a target knowledge graph, and further constructing low-order and high-order views according to the drug response information and the target knowledge graph; extracting the embedded representation of each entity in the low-order view and the high-order view by using the knowledge graph attention network, and carrying out iterative updating to generate the embedded representation of the target biological entity; performing comparative learning tasks in a single view and among a plurality of views in the low-order view and the high-order view at the same time to update the embedded representation of the entity; and carrying out nonlinear transformation on the updated embedding representation to obtain a final embedding representation, and further obtaining a reaction prediction result between the drug and the cancer cell line. According to the method, information is captured through an attention mechanism, more high-order knowledge graph information is explored by utilizing a multi-view contrast learning mechanism, and the response of a cell line to a drug can be accurately predicted.

The invention discloses a mouse liver cancer cell line with a high lung metastasis characteristic as well as a construction method and application thereof, and belongs to the technical field of biology and oncology. The cell is preserved in China Center for Type Culture Collection on February 4, 2026, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202621. The PNV-LM3 cell line provided by the invention is constructed by combining a PTEN KO and NRAS G12V mutated hydrodynamic tail vein injection model with tail vein injection in-vivo domestication, a mouse liver cancer model is successfully induced to generate lung metastasis, and the lung metastasis tendency of the cell line is greatly enhanced. Compared with a traditional Hepa1-6 cell line, the PNV-LM3 cell line has the advantages that the lung metastasis process of the liver cancer is more accurately and efficiently reproduced, and a more real experimental platform is provided for research of a liver cancer metastasis mechanism.

The invention belongs to the technical field of biomedicine, and relates to a human bladder cancer cell line ZSZB1 with primary cis-platinum drug resistance and application thereof. The cell line is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC No: C2024120, and the cell line is derived from a radical operation specimen of primary chemotherapy drug-resistant bladder cancer patients of Chinese population, and has stable in-vitro multiplication capacity and primary cis-platinum drug-resistant characteristic. The ZSZB1 provides an ideal experimental model for bladder cancer pathogenesis research, cis-platinum drug resistance mechanism exploration and novel antitumor drug screening. Establishment of the cell line can effectively promote transformation from basic research of bladder cancer to clinical application, and the cell line is of great significance to promotion of precise medical development.

The invention discloses a human-derived ampulla cancer cell line DPC-X5 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla cancer cell line is named as a human-derived ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of an ampulla cancer animal model.

This invention relates to a novel compound derived from nutmeg and an anticancer composition comprising the same. The present invention isolates several novel compounds derived from nutmeg extract and confirms that most of these novel compounds exhibit cytotoxic activity against various cancer cell lines. Five compounds (3, 4, 6, 9, and 11) were identified as having high cytotoxic activity against gastric and colorectal cancers. In particular, the compound represented by chemical formula 3 was confirmed to not only effectively induce apoptosis by regulating the cell cycle of cancer cells but also effectively inhibit tumor growth in xenograft mouse models, thus making it an effective anticancer composition.

The present invention discloses an E-DNA sensor constructed based on the size exclusion effect of a protein monolayer and its application. The E-DNA sensor comprises an Ag / AgCl reference electrode, a platinum wire counter electrode and a working electrode, wherein the working electrode is obtained by constructing a BSA self-assembled film on the surface of an AuE electrode and modifying a ssDNA probe for miRNA-21. The E-DNA sensor has a wide calibration range of 0.001-100 pM and a low detection limit of 0.48 fM, and can successfully achieve accurate evaluation of miRNA-21 expression levels in cancer cell lines and non-small cell lung cancer (NSCLC) serum samples.

The invention belongs to the technical field of organic synthesis and medicinal chemistry, and particularly relates to a synthesis method of a novel polycyclic aromatic hydrocarbon derivate 2, 6-di-tert-butyl pyrene and indolizine phenothiazine compound and application of the compound in the aspect of anti-cancer drugs. The synthesis process is simple and convenient, conditions are mild, and the yield is ideal. Pharmacodynamic evaluation shows that the compound shows strong inhibitory activity on various human cancer cell lines, and the IC50 values are respectively cervical cancer Hela cells (0.17 mu M), lung cancer A549 cells (0.3 mu M), prostatic cancer PC-3 cells (0.42 mu M) and liver cancer HepG2 cells (10.79 mu M), which are respectively reduced by 109 times, 173 times, 35 times and 1.8 times compared with positive control drug cis-platinum. In addition to efficiently inhibiting cancer cells, the compound has low toxicity to normal cells, meets the basic requirements of excellent anti-cancer drugs, and shows important application value and potential in the field of research and development of novel anti-cancer drugs.

The present invention belongs to the field of chemical medicine and discloses an EGFR proteolysis-targeted chimera, its preparation method, pharmaceutical composition, and application. The present invention provides an EGFR-degradable proteolysis-targeted chimera based on CP0371, a novel E3 ligase ligand with "molecular glue" functionality, and gefitinib, a target protein ligand. The EGFR proteolysis-targeted chimera prepared by the present invention can effectively induce EGFR degradation in cancer cell lines and has considerable bioavailability. It can be used to prepare EGFR inhibitors and can be used to form pharmaceutical compositions. It has a certain inhibitory effect on the proliferation of various tumor cells and is suitable for the development of cancer drugs for the treatment of colorectal cancer, lung cancer, esophageal cancer, glioblastoma, anal cancer, head and neck epithelial cancer, and other cancers.

The invention relates to the fields of natural medicines and medicinal chemistry, and relates to a heicogenin derivative as well as a preparation method and application thereof. The invention particularly relates to a preparation method for introducing amino acid, chlorambucil benzoate and chlorambucil butyrate derivatives at C3-OH sites of a heicogenin mother nucleus structure and application of the derivatives in preparation of anti-tumor drugs. The structure of the heicogenin spliced amino acid, chlorambucil benzoate and chlorambucil benzoate derivative and the pharmaceutically acceptable salt thereof is shown as a general formula I, II or III. Pharmacological experiments prove that the heicogenin derivative disclosed by the invention has a relatively good anti-tumor effect on human breast cancer cell lines and relatively low toxicity on human normal gastric mucosa epithelial cells GES-1, so that the heicogenin derivative has the potential of being developed into clinical anti-cancer drugs. # imgabs0 #

The invention discloses a novel anti-tumor peptide and application thereof, and is characterized in that the novel peptide is a polypeptide with the lowest binding energy with c-FLIP DED1 obtained by screening three polypeptides in Procaspase-8DED2 split protein by using a molecular docking technology, and the amino acid sequence of the polypeptide is as shown in SEQ ID NO.2; the screened polypeptide acts on a human-derived cancer cell line to obtain that the polypeptide has a good inhibition effect on tumor proliferation, and the polypeptide is expected to become an anti-tumor small-molecule polypeptide and is applied to clinical tumor treatment.

The present invention relates to a biomarker composition for predicting the prognosis of cancer malignancy induced by exposure to microplastics and use thereof, and more particularly, it was confirmed that the expression level of CD44, E-cadherin, N-cadherin, PD-L1, NPAS2, NR1D1, DNMT1, SLC7A2, PCDH7 and CLDN7 was changed in cancer cell lines and animal models treated with polystyrene microspheres which are the one type of microplastic for 4 weeks, and malignancy was induced due to an increase in proliferation, migration and invasion of cancer cells by the change in the expression level of the gene, and 5-year overall survival rates in gastric cancer patients decreased and thus the genes may be provided as a biomarker composition for predicting the prognosis of cancer malignancies by exposure to microplastics.

The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and / or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and / or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and / or neoantigens, and / or (iv) express one or more tumor fitness advantage mutations, including but not limited to acquired tyrosine kinase inhibitor (TKI) resistance mutations, EGFR activating mutations, and / or (v) express modified ALK intracellular domain(s), and / or express one or more driver mutations. Also provided herein are methods of making and preparing the vaccine compositions and methods of use thereof.

The present invention relates to a pharmaceutical composition comprising an aryl piperidine derivative compound or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of tankyrase-related cancer diseases. The pharmaceutical composition inhibits the enzymatic activity of tankyrase (TNKS), inhibits the expression of a beta-catenin target gene and the protein expression of active beta-catenin, stabilizes AXIN2 protein levels, and exhibits anti-cancer activity in a cancer cell line, so that the compound can be used as an anti-cancer agent, in particular as an anti-cancer agent. And elicits synergistic effects in combination therapy with other anti-cancer agents.

This technology provides an elucidation of the translational potential of the targeted anticancer compound Steviokine (I) and a determination of its biological properties. A series of compounds having an alkyne substituent were prepared. Steviokine and derivatives thereof were found to have high selectivity in an expanded panel of cancer cell lines. (Steviokine).

The invention belongs to the technical field of anti-tumor drugs, and particularly relates to an anti-tumor drug capable of inhibiting CCNB2 expression and application. The invention provides an anti-tumor drug capable of inhibiting CCNB2 expression. The anti-tumor drug refers to an anti-breast cancer drug; the antitumor drug is casein; or the antitumor drug is a composition formed by mixing casein and camptothecin according to the mass ratio of 1: (10-15); and the casein is alpha-S2 casein. The invention finds that casein can inhibit CCNB2 expression and can improve the effect of camptothecin in killing human breast cancer cell lines.

The present invention relates to a novel tubulin polymerization inhibitor, a method for manufacturing the same, and a pharmaceutical composition for treating cancer having the same as an active ingredient. Since the novel tubulin polymerization inhibitor compound according to the present invention or a pharmaceutically acceptable salt thereof exhibits high inhibitory ability against various cancer cell lines, it can be usefully used as a pharmaceutical composition for the prevention or treatment of cancer or as a health functional food composition for the prevention or improvement of cancer.

The present application belongs to the technical field of anti-tumor drugs, and particularly relates to an anti-tumor drug capable of inhibiting expression of CCNB2 and application. The present application provides an anti-tumor drug capable of inhibiting expression of CCNB2, wherein the anti-tumor drug is an anti-breast cancer drug; the anti-tumor drug is casein; or the anti-tumor drug is a composition of casein mixed with camptothecin at a mass ratio of 1:10-15; and the casein is alpha-S2 casein. It is found that casein can inhibit expression of CCNB2 and improve the effect of camptothecin on killing human breast cancer cell lines.

The invention discloses a breast cancer organoid transplantation tumor model construction method, and particularly relates to the technical field of breast cancer organoids, and the method comprises the following steps: 1, selecting NOD-SCID mouse immunodeficient mice, avoiding immunological rejection, feeding the mice under the condition of no specific pathogen, and ensuring the healthy state; 2, culturing the human breast cancer cell line in an incubator with the temperature of 37 DEG C, humidification and 5% CO2; 3, collecting the cultured cancer cells by using cold PBS, and quickly suspending the cells in the ice-cold Matrigel; 4, anesthetizing the mouse by using isoflurane to ensure the comfort and safety in the operation process; and 5, implanting the cell suspension into the subcutaneous part of the mouse by using an injector, so that visible tumors can be quickly formed. The breast cancer organ transplantation tumor model can be rapidly constructed, application is convenient, and the actual using effect is good.

This invention discloses a knowledge graph-based method for predicting cancer drug response, belonging to the field of bioinformatics. To address the problems of low accuracy and lack of interpretability in existing cancer drug response prediction methods, this invention constructs a knowledge graph based on heterogeneous data on the relationships between cell lines, drugs, tissues, and proteins. Multiple sub-knowledge graphs are then generated using meta-paths. A hierarchical propagation strategy based on multi-level attention is employed to extract and fuse high-order neighbor information on the sub-knowledge graphs to update the embedding representations of drugs and cell lines. Finally, after introducing drug-cell line similarity information through contrastive learning, the learned cell line-drug embeddings are used to predict the sensitivity of cancer cell lines to drugs. This invention is used for cancer drug response prediction.

Non-naturally occurring vesicles derived from bacteria, e.g., pathogenic bacteria, methods for making the vesicles, and methods for using compositions of these vesicles are disclosed. Methods of using the vesicles include prevention and / or treatment of bacterial infections. Also provided herein are compositions that include vesicles derived front bacteria and tumor vesicles, methods for making the tumor vesicles, and methods for using the compositions of bacterial vesicles and tumor vesicles. Methods of using the compositions of bacterial vesicles and tumor vesicles include treatment of cancer in a subject. Tumor vesicles may be derived from cancer cells present in the subject to be treated or from a cancer cell line expressing at least one neoantigen. The neoantigen may be specific to the subject and may have been identified by sequencing of the cancer cells from the subject. The neoantigen may be a neoantigen known to be commonly expressed in a particular type of cancer.

The application discloses an electrochemical mediation method for glycine residue α The application discloses a method for realizing post-stage azaheteroarylation of a peptide by C-H functionalization, which realizes direct azaheteroarylation of a C-H bond under electrochemical conditions by using a controllable anodic oxidation approach α The strategy does not need a transition metal catalyst, avoids metal residues, and is particularly suitable for post-stage modification of a drug peptide and a biologically active molecule; the electrochemical indirect oxidation strategy is used, reaction conditions are mild, and functional group tolerance is excellent; direct post-stage modification of a complex molecule containing a glycine residue is realized, a synthesis route is simplified, and step economy is improved. In addition, the method not only has innovative value in a peptide modification method, but also provides an effective tool for exploring a biologically active molecule with further research potential, and azaheteroarylation products obtained by using the method have an inhibitory effect on a cancer cell line.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a series of fluorine-containing neoantimycin derivatives with a neoantimycin mother nucleus structure, a preparation method of the fluorine-containing neoantimycin derivatives and application of the fluorine-containing neoantimycin derivatives in antitumor drugs, wherein the fluorine-containing neoantimycin derivatives are generated by feeding chemical precursors in the fermentation process of streptomyces S.conglobatusATCC 31005. The compound is a neoantimycin derivative containing a fluorine element, the C-2 site of the compound is connected with a carbonyl group or a hydroxyl group, the C-4 site and the C-9 site are substituted by aliphatic chains with different lengths, and the C-6 site is connected with a benzoic acid group containing an F atom or a hydroxyl group. The compounds have obvious tumor cell proliferation inhibition activity on colorectal cancer cells and lung cancer cells, the inhibition activity is equivalent to that of a control drug oxaliplatin, and the compounds have weak toxicity on non-cancer cell strains. A novel lead compound is provided for research and development of novel antitumor drugs, and the compound is expected to be developed into a tumor inhibitor.

The invention relates to a novel liposome polydopamine nanoparticle and application thereof in treating renal cell carcinoma. The preparation method of the nanoparticles comprises the following steps: adding liposome into si-circPVT1 dissolved in ribonuclease-free water, and carrying out vortex mixing to form a si-circPVT1 liposome suspension; dispersing the dopamine PDA modified liposome into a Tris-HCl solution, then adding dopamine hydrochloride, and stirring to obtain dopamine PDA modified liposome; then dispersing in a streptavidin solution, and fully oscillating at 4 DEG C under a dark condition to obtain a compound; and mixing the complex with a biotin-labeled MUC12 antibody solution for incubation, and washing the obtained suspension with a PBS (Phosphate Buffer Solution) to obtain the novel liposome polydopamine nanoparticles marked as SCLPM-NPs. The product prepared by the invention realizes targeted delivery of kidney cell cancer cell lines, and the SCLPM-NPs can effectively target tumor tissue parts and inhibit the growth of kidney tumors.